These findings provide a therapeutic option of targeting PLK4 with CFI-400945 in DLBCL, and suggest that CFI-400945 in combination with doxorubicin may improve the therapeutic outcome of patients with DLBCL. Here, PLK4 is linked to diffuse large B-cell lymphoma.